California Public Employees Retirement System Sells 6,064 Shares of IDEXX Laboratories, Inc. $IDXX

California Public Employees Retirement System cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 156,525 shares of the company’s stock after selling 6,064 shares during the quarter. California Public Employees Retirement System’s holdings in IDEXX Laboratories were worth $87,950,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of IDXX. SHP Wealth Management purchased a new stake in IDEXX Laboratories during the fourth quarter valued at $26,000. Virtus Advisers LLC bought a new position in IDEXX Laboratories during the third quarter valued at $26,000. Park Place Capital Corp purchased a new position in shares of IDEXX Laboratories in the 4th quarter worth $29,000. Mowery & Schoenfeld Wealth Management LLC grew its stake in shares of IDEXX Laboratories by 58.8% in the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after buying an additional 20 shares in the last quarter. Finally, Wormser Freres Gestion increased its holdings in shares of IDEXX Laboratories by 671.4% in the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock worth $37,000 after buying an additional 47 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Price Performance

IDXX stock opened at $567.44 on Monday. The stock has a market cap of $44.76 billion, a PE ratio of 41.78, a P/E/G ratio of 3.10 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12 month low of $513.02 and a 12 month high of $769.98. The company has a 50-day moving average price of $554.49 and a 200 day moving average price of $599.33. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period in the prior year, the company posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on IDXX. Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Citigroup started coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. Finally, UBS Group lowered their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.